U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C33H47NO3
Molecular Weight 505.7312
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TAS-108 FREE BASE

SMILES

[H][C@@]12CC[C@H](CCOC3=CC=C(CN(CC)CC)C=C3OC)[C@@]1(C)CC[C@]4([H])C5=C(C[C@@H](C)[C@@]24[H])C=C(O)C=C5

InChI

InChIKey=OHCPNHFLPCVWRG-MWSJHZLTSA-N
InChI=1S/C33H47NO3/c1-6-34(7-2)21-23-8-13-30(31(19-23)36-5)37-17-15-25-9-12-29-32-22(3)18-24-20-26(35)10-11-27(24)28(32)14-16-33(25,29)4/h8,10-11,13,19-20,22,25,28-29,32,35H,6-7,9,12,14-18,21H2,1-5H3/t22-,25-,28-,29+,32-,33-/m1/s1

HIDE SMILES / InChI

Molecular Formula C33H47NO3
Molecular Weight 505.7312
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

TAS-108 (also known as SR-16234) is a selective estrogen receptor modulator (SERM) and has been reported to have estrogen receptor (ER) α antagonistic activity and a strong affinity with a weak partial agonistic activity to ERβ receptor. It is known that ERs play a central role in the diverse actions of estrogen. TAS-108 was studied in phase II clinical trials to treat recurrent or recurrent inoperable breast cancer. In addition, TAS-108 participated in Japan in a phase II clinical trial in Endometriosis patients. The phase III studies are being planned with the drug.

Approval Year

PubMed

PubMed

TitleDatePubMed
Both N- and C-terminal transactivation functions of DNA-bound ERalpha are blocked by a novel synthetic estrogen ligand.
2003 Dec 19
TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
2005 Jan 1
Safety, tolerability and pharmacokinetics of TAS-108, a novel anti-oestrogen, in healthy post-menopausal Japanese women: a phase I single oral dose study.
2009 May

Sample Use Guides

TAS-108 was administered daily at a dose of 40 mg, 80 mg, or 120 mg to postmenopausal patients with locally advanced, or inoperable, or metastatic hormone-receptor positive breast cancer
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:14:01 UTC 2023
Edited
by admin
on Sat Dec 16 11:14:01 UTC 2023
Record UNII
42U0C8VOLO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TAS-108 FREE BASE
Common Name English
19-NORPREGNA-1,3,5(10)-TRIEN-3-OL, 21-(4-((DIETHYLAMINO)METHYL)-2-METHOXYPHENOXY)-7-METHYL-, (7.ALPHA.)-
Systematic Name English
Code System Code Type Description
PUBCHEM
9874875
Created by admin on Sat Dec 16 11:14:01 UTC 2023 , Edited by admin on Sat Dec 16 11:14:01 UTC 2023
PRIMARY
FDA UNII
42U0C8VOLO
Created by admin on Sat Dec 16 11:14:01 UTC 2023 , Edited by admin on Sat Dec 16 11:14:01 UTC 2023
PRIMARY
CAS
229634-97-3
Created by admin on Sat Dec 16 11:14:01 UTC 2023 , Edited by admin on Sat Dec 16 11:14:01 UTC 2023
PRIMARY
EPA CompTox
DTXSID601117925
Created by admin on Sat Dec 16 11:14:01 UTC 2023 , Edited by admin on Sat Dec 16 11:14:01 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY